Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?
Phase 1
- Conditions
- Prostate cancerTherapeutic area: Diseases [C] - Male Urogenital Diseases [C12]
- Registration Number
- CTIS2024-511104-16-00
- Lead Sponsor
- Turku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
Men with histologically confirmed prostate cancer, Age 50-85 years at baseline, WHO performance score 0-2, At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single-photon emission computed tomography (SPECT) imaging, All previous treatment lines are allowed, Patient signs informed consent form after receiving written information
Exclusion Criteria
Patient is not able to understand the purpose of the study, Medical conditions prohibiting whole-body PET/CT imaging
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method